Biopharma to raise more than 1,000 drug prices in 2025, advisory firm predicts
Drugmakers are expected to increase list prices on more than 1,000 medicines this year, and already raised the prices on about 250 drugs on Jan. 1, according to an analysis by the consultancy firm 3 ...
View ArticleAfter CagriSema, eyes are on Lilly’s oral GLP-1 as next key obesity play
With the disappointment of Novo Nordisk’s injected CagriSema in obesity at the end of 2024, there are questions around how much more injected next-gen weight loss ...
View ArticleGSK’s Nucala bags another China approval, but biggest test yet to come
GSK’s blockbuster respiratory drug Nucala has secured a China label expansion for certain patients with inflamed sinuses. But a more important challenge on the way to hitting its multibillion-dollar...
View ArticleNovo petitions FDA over Victoza compounding as first generic wins approval
Novo Nordisk is continuing its citizen petition crusade at the FDA, this time aiming to stop the compounding of Victoza, its blockbuster GLP-1. The push comes as the regulator late last month
View ArticleEli Lilly seeks to join lawsuit over end of tirzepatide shortage
Eli Lilly has asked to intervene in litigation between a compounding pharmacy trade group and the FDA over the agency’s decision to remove Lilly’s blockbuster obesity and diabetes drug tirzepatide from...
View ArticleFlorida car dealer joins insulin pricing fight against Eli Lilly, Sanofi
A Florida-based car dealer has joined mounting litigation against Eli Lilly, Novo Nordisk and Sanofi over what it calls the “exorbitant” price of insulin. Braman Motors is the first private company to...
View ArticleNeumora fails Ph3 depression study; Our review of 2024 megarounds; Pfizer...
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add...
View ArticleEuropean macrocycle startup Orbis raises €90M
As interest grows in the ability to leverage certain ringed molecules as drugs, Orbis Medicines has raised €90 million in new funding less than a year since the company unveiled its seed round. Orbis’...
View ArticleOculis’ eye drug clears Phase 2 in France as US development beckons
Oculis kicked off the year on a positive note with a mid-stage success in a rare ophthalmic condition, setting the stage for clinical development in the US. The Swiss drugmaker’s serum glucocorticoid...
View ArticleFDA drug approvals 2024: Rare diseases, schizophrenia and Alzheimer's
2024’s novel drug approvals offered a wide array of new cancer drugs, rare disease treatments, a potential Alzheimer’s blockbuster, and about 10 fewer approvals than 2023. While 2022 and 2023 saw major...
View ArticleI-Mab stops work on CD73; Citius to pursue ‘strategic’ options
Plus, news about General Proximity and PBS Biotech: I-Mab pauses CD73 development: The company is not moving forward with a program called uliledlimab to focus on a separate drug, a bispecific ...
View ArticleExclusive: Joe Jimenez's Aditum Bio rings in new year with $428M third fund
The first biopharma venture fund to close in 2025 comes from industry veterans Joe Jimenez and Mark Fishman, two former Novartis leaders. Jimenez exclusively told Endpoints News on Monday that Aditum...
View ArticleWuXi Biologics to sell Irish vaccine site to Merck for $500M
WuXi Biologics’ subsidiary WuXi Vaccines is divesting a manufacturing facility in Dundalk, Ireland, to Merck for $500 million, roughly a week after WuXi AppTec also announced it's shrinking its...
View ArticleAnthem Biosciences eyes $397M public offering in India
India-based drug manufacturer Anthem Biosciences has its sights on going public with an IPO that could raise 34 billion rupees ($397 million). Anthem filed its proposed IPO with the Securities and...
View Article'Microprotein' biotech Velia, backed by TCG and Foresite, to wind down
San Diego-based Velia Therapeutics, which was working on so-called microproteins, is in the process of winding down about two years after a $55 million Series A, CEO John McHutchison told Endpoints...
View ArticleNew FDA guidance on accelerated approvals, AI, clinical trials
With two weeks until President-elect Donald Trump's administration takes over, the FDA on Monday released dozens of new draft and final guidance documents covering everything from how to reliably use...
View ArticleTeoxane issues competing buyout bid for Revance and its Botox rival
Revance Therapeutics’ contract dispute with a Swiss partner has caused hiccups in its plan to be acquired by Crown Laboratories. Now that partner says it can offer Revance a better deal. Teoxane on...
View ArticleUpdated: Acelyrin’s stock drops due to mixed Phase 2 data in thyroid eye disease
Acelyrin has offered a more detailed look at mid-stage results for its thyroid eye disease drug candidate as it tees up its next development steps. In the latter part of a Phase 1/2
View ArticleExclusive: Forbion-backed cardio biotech rebrands to RyCarma with Phase 2 plans
A 20-year-old biotech working on small molecule treatments for cardiovascular and skeletal muscle diseases has rebranded and plans to enter Phase 2 in heart failure later this year. Formerly known as...
View ArticleHighlander Health acquires Target RWE to improve clinical trials
Highlander Health, the clinical trial startup co-founded by former Verily execs Amy Abernethy and Brad Hirsch, is acquiring data company Target RWE. Launched in September, Highlander wants to make it...
View Article